Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc
Journal website http://www.jocmr.org

Original Article

Volume 7, Number 5, May 2015, pages 303-307

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects

Figures

Figure 1.
Figure 1. Outlines of studies 1 and 2.
Figure 2.
Figure 2. Changes in clinical parameters after 12 and 24 weeks in study 1: (a) HbA1c; (b) 2-h postprandial plasma glucose; (c) body weights; (d) insulin doses. *P < 0.05 compared with the baseline.
Figure 3.
Figure 3. The changes in clinical parameters after 12 and 24 weeks in study 2: (a) HbA1c; (b) 2-h postprandial plasma glucose; (c) body weights; (d) insulin doses. *P < 0.05 compared with the baseline.
Figure 4.
Figure 4. The correlations between ΔHbA1c and BMI at baseline in study 1 (a) and study 2 (b), and between ΔHbA1c and HbA1c at baseline in study 1 (c) and study 2 (d).

Table

Table 1. Characteristics of the Patients in Each Study Group
 
Study 1Study 2
Number of subjects3621
Age (years)64.1 ± 11.357.5 ± 12.5
Sex male/female (%)63.9/36.147.6/52.4
Durations for diabetes (years)14.4 ± 6.713.4 ± 4.7
Body weight (kg)71.1 ± 14.970.5 ± 12.8
BMI (kg/m2)26.8 ± 5.127.1 ± 4.6
HbA1c (NGSP) (%)8.1 ± 1.29.0 ± 1.6
2-h postprandial plasma glucose (mg/dL)164.7 ± 64.7200.2 ± 83.2
2-h postprandial CPR (ng/mL)2.5 ± 2.31.9 ± 1.7
Insulin total doses (units)35.2 ± 17.130.4 ± 17.0